Lesser Known Ankylosing Spondylitis Pharmacotherapy is an Untapped Market in the United States, Finds Frost & Sullivan

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 3
• Langue: English

Extrait

Lesser Known Ankylosing Spondylitis Pharmacotherapy is an Untapped Market in the United States, Finds Frost & Sullivan

PR Newswire MOUNTAIN VIEW, California, Oct. 10, 2012

-- Additional therapeutic options are needed for patients who fail to respond to the current therapy

MOUNTAIN VIEW, California,Oct. 10, 2012/PRNewswire/ -- The treatment beyond standard of care for ankylosing spondylitis (AS) pharmacotherapeutics currently consists of a single drug class – tumor necrosis factor (TNF) inhibitors. This unavailability of alternative treatment represents an underserved and potentially significant market that is waiting for exploration.

New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com)United States Market for Ankylosing Spondylitis Pharmacotherapyresearch finds that the market earned revenues of more than$496.6 millionin 2011 and estimates this to reach$986.3 millionin 2017.

If you are interested in more information on this research, please send an email toBritni Myers, Corporate Communications, [e-mail], with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

AS is a chronic, inflammatory and genetically related disease that, being highly heritable, translates to a market with a stable patient population. Given that awareness is low, many cases go undiagnosed for years, signifying a much larger opportunity than previously estimated.

"Disease education campaigns could effectively boost the number of patients seeking diagnosis and treatment," saidDeborah Toscano. "There will be a strong market for advanced,Frost & Sullivan Senior Industry Analyst affordable, and disease-modifying drugs with improved safety and true clinical benefits."

Since TNF inhibitors are a well established therapeutic drug class, they are likely to continue to be used as the first line of treatment in the foreseeable future. TNF inhibitors, as a drug class, have laid the groundwork for the next generation of effective disease modifying antirheum atic drugs and biologics with improved safety and efficacy profiles.

Although therapies such as TNF inhibitors are effective in rheumatoid arthritis as well as ankylosing spondylitis, there is still a large market for specialty drugs. There is substantial potential for alternatives for patients with moderate to severe forms of the disease, who do not respond to these medications. While many patients take well to non-steroidal anti-inflammatory drugs (NSAIDs), there is an unmet need for treatment aimed at symptom relief and slowing of disease progression.

The development of these therapies, however, is hindered by several factors, including the incompletely understood pathogenesis of AS. As medical advances continue to unfold the mechanism of this complex disease, more druggable targets will be discovered, leading to prospective new remedies.

"New participants may struggle to gain market share due to low patient awareness," noted Toscano. "Nevertheless, aggressive marketing efforts that include patient and physician education could improve the uptake of AS drugs."

The launch of novel therapies and the ensuing promotional campaigns by competitors will revive interest in AS, stoking commercial acceptance and market expansion.

United States Market for Ankylosing Spondylitis Pharmacotherapyis part of theLife SciencesGrowth Partnership Services program, which also includes research in the following markets: United States Market for Rheumatoid Arthritis Pharmacotherapy, United States Rheumatic Diseases Therapeutics Market, United States Market for Psoriatic Arthritis Pharmacotherapy, and U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, w orks in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Propositionprovides support to our clients throughout all phases of their journey to